1196GDF-15 neutralizing antibody visugromab increases intratumoral immune cell infiltration to support bispecific T-cell engagersdoi:10.1136/jitc-2023-SITC2023.1196Background GDF-15, a member of the TGF-beta superfamily, is a critical factor of feto-maternal tolerance, but also of local immune ...
(GDFATHER-1/2a trial, NCT04725474), patients with advanced cancers refractory to anti-PD-1 or anti-PD-L1 therapy (termed generally as anti-PD-1/PD-L1 refractoriness) were treated with the neutralizing anti-GDF-15 antibody visugromab (CTL-002) in combination with the anti-...
(GDFATHER-1/2a trial,NCT04725474), patients with advanced cancers refractory to anti-PD-1 or anti-PD-L1 therapy (termed generally as anti-PD-1/PD-L1 refractoriness) were treated with the neutralizing anti-GDF-15 antibody visugromab (CTL-002) in combination with the anti-PD-1 antibody ...
A new study published in Nature reports results from the phase I/IIa study GDFATHER, showing synergistic effects of the neutralizing anti-GDF15 antibody visugromab in combination with the anti-PD1 antibody nivolumab in patients with urothelial cancer. This trial builds on results in preclinical ...
Consistent with this, the administration of rGDF15 reduced the markers of inflammation in serum [53], while the administration of a neutralizing antibody against GDF15 to obese mice increased the levels of inflammatory markers in adipose tissue [54]. Likewise, mice with a reduced mitochondrial ...
GDF-15-neutralizing antibody could reverse cachexia symptom but not muscle loss in experimental mice [87]. Cachexia symptom in mice could be alleviated by GDF-15 monoclonal antibody [88]. Cisplatin increased serum GDF-15 concentration in anorexia mice, which was not affected by GFRAL-/- mice [...
(Fig.2d, e). Thus, GDF-15 impairs T cell adhesion primarily by interfering with the ICAM-1:LFA-1-axis. Surprisingly, flow cytometry failed to show effects of GDF-15 on the binding of the conformation-specific anti-active-LFA-1 antibody mAb24 (Fig.2f) or an Fc-tagged ICAM-1 complex...
Each lot of this antibody is quality control tested by neutralizing the differentiation induced by recombinant human BMP-14 (GDF-5) (Cat. No. 779506) at 1.5 ?g/mL on ATDC5 mouse chondrogenic cells. ND50range: 3?– 15??g/mL. It is recommended that the reagent be titrated for optimal ...
The affinity of the neutralizing antibody for BMPR-IA (K D = 2.2 nM) is higher than that of GDF-5 for BMPR-IA (K D = 20 nM) but slightly lower than the receptor affinities of BMP-2 (K D = 0.8 nM) or GDF-5 R57A (K D = 1.6 nM). In summary, our data...
first reported that mice bearing tumors engineered to overexpress GDF15 lost weight dramatically (Johnen et al., 2007). This could also be reproduced by injection of recombinant GDF15 and prevented by a neutralizing GDF15 antibody. Transgenic GDF15-expressing mice similarly lost weight secondary to...